Phase 2 Trial of Donafenib in 131I-Refractory Differentiated Thyroid Cancer

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2016
Donafenib for advanced 131I-refractory/resistant differentiated thyroid cancer(DTC).
Epistemonikos ID: 8bc83175c01ea5218f90a307dc521e3616eb0b17
First added on: May 17, 2024